What should be communicated to a client taking lisinopril who is trying to become pregnant?

Communicating to a client taking lisinopril who is trying to become pregnant is critical, as this medication is classified as an ACE inhibitor, which is known to carry risks during pregnancy, especially in the second and third trimesters. It is associated with potential fetal harm, including issues such as renal dysfunction, oligohydramnios, and even complications leading to fetal death. Therefore, advising a client to substitute lisinopril for another medication during pregnancy is the most responsible and appropriate action.

Before conception and during pregnancy, it is important to evaluate the safety of any medication. While certain medications may be deemed safe or have minimal risks, lisinopril is generally not recommended due to the known adverse outcomes associated with its use during pregnancy. Alternative antihypertensive medications that are safer for use during pregnancy, such as methyldopa or labetalol, may be suggested instead. This ensures both the health of the mother and the developing fetus are prioritized.

The other options do not align with best practices: claiming the medication is safe undermines the potential risks; advising to continue taking it as prescribed ignores the need for medication reassessment; and suggesting high doses of folic acid, while beneficial during pregnancy, does not address the